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Abstract
Background: Subfertility is a common problem for which in vitro fertilisation (IVF) treatment is commonly recommended.
Success rates following IVF are suboptimal and have remained static over the last few years. This imposes a considerable
financial burden on overstretched healthcare resources. Time-lapse imaging (TLI) of developing embryos in IVF treatment is
hypothesised to improve the success rates of treatment. This may be either by providing undisturbed culture conditions or
by improving the predictive accuracy for optimal embryo selection from a cohort of available embryos. However, the current
best evidence for its effectiveness is inconclusive.
Methods: The time-lapse imaging trial is a pragmatic, multi-centre, three-arm parallel-group randomised controlled trial
using re-randomisation. The primary objective of the trial is to determine if the use of TLI or undisturbed culture in IVF
treatment results in a higher live birth rate when compared to current standard methods of embryo incubation and
assessment. Secondary outcomes include measures of clinical efficacy and safety. The trial will randomise 1575 participants to
detect an increase in live birth from 26.5 to 35.25%.
Discussion: In the absence of high-quality evidence, there is no current national guidance, recommendation or policy for
the use of TLI. The use of TLI is not consistently incorporated into standard IVF care. A large, pragmatic, multi-centre, trial will
provide much needed definitive evidence regarding the effectiveness of TLI. If proven to be effective, its incorporation into
standard care would translate into significant clinical and economic benefits. If not, it would allow allocation of resources to
more effective interventions.
Trial registration: ISRCTN registry ISRCTN17792989. Prospectively registered on 18 April 2018
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Introduction
Background and rationale {6a}
Background
Subfertility is a common problem affecting 1 in 7 couples.
In vitro fertilisation/intracytoplasmic sperm injection
(IVF/ICSI) is a fertility treatment often recommended to
these couples. It involves fertilisation of the oocytes with
sperm in the laboratory to create embryos. The best one
or two embryos are then selected for transfer back into
the womb.
Increasing demand for treatment The number of
women having IVF has seen a steady increase over the
years from 14,057 in 1992 to 52,288 in 2014 in the UK,
with the latest national report showing approximately
68,000 treatment cycles performed annually in the UK
in 2014 [1]. The National Institute of Health and
Clinical Excellence (NICE) recommends 3 NHS-funded
treatment cycles per couple [2].
Static success rates Success rates following IVF are
suboptimal and have remained static over the last few
years. European registers report an average of 32%
clinical pregnancy rate in fresh (excluding treatment
with frozen embryos) IVF cycles (2013), and in the UK,
the Human Fertilisation and Embryology Authority
(HFEA) reports a 26.5% live birth rate for fresh IVF
cycles for 2013 [1]. European registries and UK data
show no improvements in live birth rate over the last 3
years.
Economic considerations Forty per cent of IVF
treatments in the UK are funded by the NHS at the
average tariff of £3500 per treatment cycle, imposing a
considerable financial burden on overstretched NHS
resources.
Multiple births Transferring two embryos back into the
womb (double embryo transfer [DET]) is a common
practice in IVF/ICSI in order to maximise the chance of
pregnancy. DET however results in a much higher
percentage of multiple pregnancies, between 24 and
36%, as compared to single embryo transfers [1].
Multiple pregnancies are associated with an increase in
perinatal morbidity and mortality and increased
maternal morbidity. The short- and long-term health
burden from this increased morbidity has implications
Bhide et al. Trials          (2020) 21:600 Page 2 of 17
for the children and parents, as well as the NHS and
other publicly funded services. Transferring only a single
embryo back into the womb (elective single embryo
transfer [e-SET]) can reduce the risk of multiple preg-
nancies but has the potential to reduce success rates.
However, e-SET is used in only around 30% of all trans-
fers, and as a result, multiple pregnancy rates following
IVF/ICSI are still approximately 15% compared to 1.6%
in natural conceptions [1].
Pregnancy rates following IVF/ICSI are positively
correlated with appropriate and optimal embryo
selection from the available cohort of embryos. The
current methods of embryo selection have poor
predictive accuracy. If the prediction of the implantation
potential of embryos could be improved, this would not
only improve the overall live birth rates following
treatment but also facilitate embryo selection for single
rather than double embryo transfer to reduce multiple
birth rates. Embryo selection to improve pregnancy rates
remains a significant challenge in IVF. NICE [2] and a
recent commentary from the British Fertility Society
(BFS) and Association of Clinical Embryologists (ACE)
[3] recommend further research to improve embryo
selection to facilitate single embryo transfers.
Rationale
Time-lapse imaging (TLI) of the developing embryos is a
new technology available in IVF/ICSI laboratories. It
involves digital imaging of the developing embryos at
intervals of every 5–15min from the time of IVF/ICSI
up to day 5 of culture. These images are used to create a
time-lapse sequence of embryo development visualised
on an external monitor using specialised computer soft-
ware. TLI systems may confer a dual advantage over
conventional systems. They allow morphological assess-
ment of embryos without the need for removal of em-
bryos from the incubators, giving a potential advantage
of undisturbed culture conditions for the embryos. TLI
also allows the embryologists to gain more information
about embryo development, especially transient events
which may be missed by traditional assessment methods
by the generation of variables called ‘morphokinetic pa-
rameters’. By providing undisturbed culture conditions
and/or the addition of morphokinetic parameters to
standard methods of embryo selection, TLI is hypothe-
sised to improve the predictive accuracy for optimal em-
bryo selection from a cohort of available embryos and
hence the success rates for treatment.
Existing research
A systematic review on this topic was published in
February 2015 by the Cochrane Collaboration [4]. This
review aimed to assess the effect of TLI compared with
standard practice on live birth, clinical pregnancy,
miscarriage and stillbirth rates. The authors acknowledged
the effect of two variables in the TLI systems, undisturbed
culture and morphokinetic parameters, and aimed to
assess not only the overall impact of the system but the
relative and independent contributions of these two
variables. This review included only three randomised
controlled trials (RCTs), with a total of 994 participants.
Only one trial assessed live birth rate, and due to the small
sample size (n = 76), results were imprecise and
inconclusive (OR [TLI vs. standard practice] 1.1, 95% CI
0.5 to 2.7, moderate-quality evidence). Likewise, results re-
garding clinical pregnancy, miscarriage and stillbirth rates
were also inconclusive; this was partly because the two
moderate quality studies had very small sample sizes (n =
76, n = 62), while the third, larger study (n = 856) was
assessed as having a high risk of bias. Two of the above
three studies assessed the impact of TLI due to undis-
turbed culture only, without the addition of morphoki-
netic parameters to standard care. This showed no
conclusive differences in live birth, miscarriage and still-
birth rates. The third, larger study compared the com-
bined effect of morphokinetic parameters and undisturbed
culture to standard care, which showed no conclusive dif-
ferences in clinical pregnancy rates. An update to this re-
view was published in 2018 and presented the same
conclusions [5].
A recent meta-analysis by Chen et al. [6] reiterated the
findings of the Cochrane review. A study by Goodman
et al. [7] showed no significant advantage of the addition
of morphokinetic parameters to undisturbed culture,
when all embryos were cultured in a closed system.
Again, this trial reported clinical pregnancy rate rather
than live birth rate as its primary outcome with no
health economic evaluation.
In conclusion, the current best evidence has provided
inconclusive evidence regarding the effectiveness of
time-lapse imaging. In the absence of high-quality evi-
dence, there is no current national guidance, recommen-
dation or policy for the use of time-lapse imaging in
IVF/ICSI. The use of time-lapse imaging is not consist-
ently incorporated into the standard plan of IVF/ICSI in
IVF centres across the UK. It is however available at
many centres, where it is offered to couples usually at an
extra charge. A large, pragmatic, multi-centre, trial
would provide much needed definitive evidence regard-
ing the effectiveness of TLI for patients.
Potential risks and benefits
There is no added risk foreseen by using time-lapse im-
aging technology. Any devices used in this trial are CE-
marked and used within their certified indication. Time-
lapse imaging requires exposing embryos to infrared
light for about 15 ms every 5 to 15min; this light expos-
ure has been tested and found to be equivalent to light
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exposure using standard incubators [8]. The hypothe-
sised benefit of TLI is that it will improve the rate of
IVF/ICSI success, either by improving selection through
analysis of morphokinetic parameters or by allowing em-
bryos to develop in an undisturbed culture.
Why this research is urgently needed now
Inconclusive and inadequate evidence As stated above,
the current best evidence for the use of time-lapse im-
aging in IVF/ICSI is inconclusive. Previous RCTs have
typically used the clinical pregnancy rate as a surrogate
outcome for the live birth rate, which remains the most
relevant outcome for patients, clinicians and policy-
makers. Furthermore, the long-term safety of this pro-
cedure is unknown.
Clinical equipoise In preparation for the trial, a survey
was sent out to lead clinicians and embryologists across
the UK to assess their views on the use, effectiveness
and the need for conclusive evidence on the use of TLI.
Of those who responded, 100% agree that a well-
planned randomised controlled trial is essential. A state
of clinical equipoise was registered by 70% of the re-
spondents. We also surveyed patients’ opinion through
our collaborators Fertility Network UK. Seventy-three
per cent of 80 respondents were in a state of participant
equipoise, and 100% agree that a definitive conclusive
trial is necessary.
Widespread use TLI in IVF/ICSI is commercially
available, extensively marketed and widely introduced in
IVF clinics in spite of clinical equipoise and inconclusive
evidence regarding its effectiveness. The systems impose a
considerable additional expense to clinics in the form of
capital costs, running costs, consumables and embryology
time. Couples who pay for the treatments are charged
between £350 and 1000 for TLI, which is almost an
additional 25% of the cost of the standard IVF/ICSI
treatment. In the absence of high-quality evidence and
rapidly slipping clinical equipoise, it is necessary to ur-
gently perform a large randomised controlled trial to
confirm or refute the benefit of time-lapse imaging in
IVF/ICSI.
Objectives {7}
Primary objectives
The primary objective of the trial is to determine if the
use of TLI or undisturbed culture in IVF/ICSI treatment
results in a higher live birth rate when compared to
current standard methods of embryo incubation and
assessment.
Secondary objectives
The trial aims to answer the following questions, and
the secondary objectives of the trial are as follows:
1) To obtain measures of the clinical effectiveness of
TLI/undisturbed culture:
 Are clinical pregnancy rates and implantation
rates increased with the use of TLI/undisturbed
culture in IVF/ICSI treatment?
 Does the use of TLI/undisturbed culture increase
the number of women having an elective single
embryo transfer?
2) To obtain measures of clinical safety of TLI/
undisturbed culture:
 Does the use of TLI/undisturbed culture
decrease the incidence of multiple births
following IVF/ICSI treatment?
 Does the use of TLI/undisturbed culture
decrease the incidence of miscarriages following
IVF/ICSI treatment?
 Are stillbirths and major congenital
abnormalities at birth decreased with the use of
TLI/undisturbed culture in IVF/ICSI treatment?
Trial design {8}
Study design
The trial is a pragmatic, multi-centre, three-arm
parallel-group randomised controlled trial using re-
randomisation.
The hypothesised benefit of the TLI systems may be
due to either a closed undisturbed culture system or the
use of morphokinetic parameters for embryo selection
or both. Hence, a three-arm study design is necessary to
answer the research question and define the contribu-
tions of both the variables involved.
The trial will compare the results of the following:
1) Intervention 1: incubation and assessment of
embryos using TLI systems (morphokinetic
parameters + undisturbed culture + morphological
assessment)
2) Intervention 2: incubation of embryos in
undisturbed culture and standard embryo
assessment (undisturbed culture + morphological
assessment)
3) Control: standard care (morphological assessment
alone)
The design of this trial will be pragmatic. It will allow
centres to use a TLI system of their choice. The trial
tests the basic premise that undisturbed culture and/or
addition of morphokinetic parameters to standard
embryo assessment improves outcomes in IVF/ICSI
treatment. It does not aim to test nor validate individual
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TLI systems and algorithms. The trial will use the
manufacturer’s algorithm for morphokinetic parameters
as a minimum standard to ensure quality control and
external validity to the study. It will allow centres to
develop more sophisticated centre-specific algorithms by
incorporating further parameters into the basic model
recommended by the manufacturer. It is accepted that
clinical protocols for IVF and laboratory conditions will
vary with each centre. All clinical and laboratory ele-
ments of IVF/ICSI treatment apart from the randomised
intervention will be carried out according to local
centre protocols, ensuring only that there is no vari-
ation across the three study arms in culture medium
and incubator settings (temperature, CO2 and O2
levels) within each centre.
Couples having IVF/ICSI treatment will be eligible for
the trial. Eligible participants will be screened in the
fertility clinics and invited to participate in the trial.
Following informed consent from both partners,
participants will be randomised in a 1:1:1 ratio to one of
the three arms: TLI, undisturbed culture or standard care.
Women will be followed up until either a negative
pregnancy test 2 weeks after embryo transfer or to the end
of their pregnancy following a positive pregnancy test.
A consort flow chart is attached as Additional file 1.
Methods: participants, interventions and
outcomes
Study setting {9}
This is a multi-centre trial being carried out at centres
across the UK and internationally. Participants will be
recruited at UK HFEA-licenced as well as international
fertility centres that have full IVF/ICSI laboratory ser-
vices available.
Eligibility criteria {10}
Inclusion criteria
The inclusion criteria are broad in keeping with the
latest NICE guidelines (2013) for NHS-funded IVF/ICSI
treatment.
Participants undergoing IVF/ICSI treatment and:
1) The woman is between 18 and 42 years of age at
the time of consent
2) The male partner is at least 18 years of age at the
time of consent
3) Receiving the first, second or third IVF/ICSI
treatment cycle
4) Both partners give written informed consent
5) Those having at least 3 2PN embryos (showing 2
pro-nuclei which is a sign of normal fertilisation) on
day of fertilisation check
Exclusion criteria
1) Participants concomitantly participating in other
interventional trials
2) IVF/ICSI treatment using donor gametes
3) Planned pre-implantation genetic diagnostics or
screening (PGS/PGD)
The study is open to any sites willing to randomise
participants to the 3 treatment groups, use standardised
gas, temperature and media for all 3 incubation methods
and for embryologists to adhere to specific quality
control detailed below to maximise allocation adherence
and maintaining the study blind.
Who will take informed consent? {26a}
Screening
Potentially eligible participants at the recruiting IVF
clinics will be identified at routine clinic appointments
before the start of their IVF/ICSI treatment and will be
given a letter of invitation to participate in the trial.
Those interested will see a member of the research team
who will give them detailed verbal information and a
participant information sheet (PIS). Participants will
have ample time to read the information leaflets, ask any
questions and make an informed choice of whether to
participate or not. A minimum of 24 h is recommended
for couples to consider the trial, although well-informed
participants can be consented sooner than that if the
local research team believes they have a good under-
standing of the trial and their involvement in it. If partic-
ipants agree to be a part of the trial, they will be
consented at the next available opportunity.
Informed consent
Informed consent of both partners will be taken by a
trained and delegated member of the study team. This
will be done at their clinic appointment or subsequent
visits to the clinic up until but prior to the egg collection
procedure.
Consent will be confirmed by the doctor performing
the egg collection on the day of the procedure, and this
confirmation of consent will be documented in the
woman’s medical notes. Some participants who have
consented as they fulfil all other eligibility criteria will
not be randomised to the trial due to an inadequate
number of eggs or embryos, or because of insufficient
capacity in all incubator types at the time of
randomisation. Such participants may still participate in
the trial in subsequent treatment attempts but will need
to be consented again. In addition, those participants
who were randomised previously can be consented and
randomised again, as long as they continue to meet all
trial inclusion criteria.
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A copy of the consent form will be given to the
participants; one copy will be kept in the woman’s
hospital notes and one will be placed in the Investigator
Site File. Only members of the research team
documented on the delegation log will be able to
consent eligible couples for participation in the study.
The consenting staff will have thorough knowledge and
documented training of research governance issues
surrounding consent and will be fully conversant with
the study protocol.
The qualified person taking consent must explain to
the potential participants that they are free to refuse any
involvement within the study or alternatively withdraw
their consent at any point during the study and for any
reason. If there is any further safety information that
may result in significant changes in the risk/benefit
analysis, the PIS and informed consent form (ICF) will
be reviewed and updated accordingly. All participants
that are actively enrolled in the study will be informed of
the updated information and given a revised copy of the
PIS and ICF in order to confirm their wish to continue
in the study (if feasible), if it may change their
willingness to participate. Participants who speak limited
English can only be consented and included in the trial
if translation has been provided by an independent
translator (i.e. not a family member) or through the
Language Line translation service for UK sites.
International sites will translate patient-facing documen-
tation into the required language.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Not applicable as there are no ancillary studies planned
for the trial.
Interventions
Explanation for the choice of comparators {6b}
The hypothesised benefit of the TLI systems may be due
to either a closed undisturbed culture system or the use
of morphokinetic parameters for embryo selection or
both. Hence, a three-arm study design is necessary to
answer the research question and define the contribu-
tions of both the variables involved. The comparator for
both the intervention groups 1 and 2 (TLI and undis-
turbed culture) will be standard care, i.e. embryo incuba-
tion using a conventional, non-TLI incubator and
embryo selection based solely on morphological assess-
ment, and necessitating removal of the embryo from the
incubator for examination under a light microscope.
This is the ideal comparator as allows comparison to
groups 1 and 2 in terms of (a) efficacy of morphokinetic
parameters given by time-lapse imaging and (b) efficacy
of undisturbed culture provided by the time-lapse incu-
bator. To date, this method is seen as the standard of
care in the absence of evidence that time-lapse imaging
provides superior results.
Intervention description {11a}
Care pathway
Participants will start their IVF/ICSI treatment and will
follow the steps for the standard care pathway to the point
of IVF or ICSI. This will include controlled ovarian
stimulation with exogenous hormones, final maturation
trigger for the release of eggs, sperm production, egg
collection with a minor surgical procedure and the
procedure of IVF or ICSI as indicated. Media and all other
standard laboratory conditions will vary with recruiting
centres but will remain the same for all three arms within
the particular centre. Consent for the trial will be taken at
clinic appointments or subsequent visits to the clinic up
until but prior to the egg collection procedure.
Differences in the care pathway/trial intervention will
involve the steps of embryo incubation, assessment and
selection for transfer into the womb. Following the trial
intervention, all further care, which includes embryo
transfer, pregnancy test and review appointments, will
be according to the standard care pathway.
Eligibility check
Prior to randomisation, a final eligibility check will be
carried out. Participants having IVF or ICSI will need at
least 3 2PN embryos (showing 2 pro-nuclei which is a sign
of normal fertilisation) on the day of fertilisation check.
Randomisation will be done only subject to availability of
a space in incubators for each arm of the study.
Ineligible and non-randomised participants
Some participants who have been consented will not be
eligible for randomisation due to inadequate numbers of
eggs or embryos. A member of the research team will
inform these participants that they have not fulfilled the
eligibility criteria. These participants will continue to
have standard care according to local protocols.
Trial intervention/allocation
Participants who have at least three fertilised embryos (2
pro-nuclei) on the day after egg collection will be ran-
domly allocated to one of the following three groups:
1. Participants in the first/time-lapse imaging arm
(intervention 1) will have embryo assessment and
scoring with the morphokinetic parameters
obtained from the time-lapse imaging system in
addition to the standard morphological embryo
scoring systems in undisturbed culture conditions
in the time-lapse imaging incubators.
2. Those in the second/undisturbed culture arm
(intervention 2) will have embryo assessment
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obtained using only conventional morphological
embryo assessment in undisturbed culture
conditions in the time-lapse imaging incubators. No
morphokinetic assessment will be performed in this
group.
3. Those in the third/standard care arm (control) will
have an embryo assessment obtained using only
conventional morphological embryo assessment
using the light microscope and standard embryo
culture in standard incubators.
Each recruiting centre may use a TLI system of their
choice. However, the same TLI system will be used in
both intervention arms 1 and 2 at each individual centre,
either as a high-quality incubator providing undisturbed
culture condition alone or with the addition of the mor-
phokinetic parameters.
Laboratory procedures
Egg collection and fertilisation Egg collections will be
performed between 35 and 38 h after the ovulation trigger
injection. These eggs will be kept in the standard
incubators until the next procedure which is insemination
for IVF or removal of cumulus cells and injection of
sperm for ICSI. Timing of the ICSI or the standard
insemination will vary depending on the time of
fertilisation check of the laboratory. Fertilisation checks
will be completed, and the fertilised oocytes/embryos will
be placed in the appropriate incubators based on
randomisation between 16 and 19 h from the ICSI/
insemination procedure. As all embryos will be in
standard incubators at the time of fertilisation check, the
is important and specified to make sure that the
annotations for the time-lapse incubator start from PN
fading to get maximum information for embryo selection.
Standardised settings for incubators Although the
laboratories can follow their own centre protocols, they
should make sure that there are no other variables
between the study groups other than the study
intervention. Particular attention should be given to the
following:
– The culture media used in all three trial groups to
be the same.
– Time-lapse incubators use triple gas and therefore
the standard incubators used in the trial have to be
on triple gas as well. In addition, the gas
concentrations are to be the same (CO2, O2 and N2)
in all the incubators. The actual gas concentrations
may vary from centre to centre depending on the
culture medium used and the local protocols.
However, the concentrations need to be the same
across all three arms and in all trial incubators.
– All incubators used in the trial to be set at the same
temperature.
– All the oocytes from participants consented for the
trial have to be kept in the standard incubator on
the day of egg collection after ICSI or insemination.
(If any patient has only one or two oocytes injected
or inseminated, then they are not eligible for the
trial, and therefore, the lab can culture them in any
incubator).
– On day 1 after egg collection, the fertilised eggs are
allocated to the appropriate incubators according to
the randomisation. (If any patient has only one or
two oocytes fertilised, then they are not eligible for
the trial, and the lab can culture them in any
incubator.)
Documentation of allocation Once randomisation is
performed, this information should not be stated in the
patient notes or any document that goes into the patient
notes as all staff except embryologists are blinded for the
trial. Embryologists should have a separate randomisation
sheet that can be kept in the lab only.
Embryo grading The embryo grading will be performed
on day 3 and day 5 (and, if needed, on day 6). The
morphological grading on day 3 will take account of the
number of cells/blastomeres, the regularity of blastomeres
and the degree of fragmentation. The grading on day 5
will be based on the expansion of blastocyst, inner cell
mass and trophectoderm. The Association of Clinical
Embryologists (ACE) embryo grading scheme introduced
in April 2017 will be followed to grade the embryos on
day 3 and day 5.
Embryo selection The selection of embryos for transfer
will be as follows:
– For embryos in all three treatment groups, all the
available embryos will be graded on the basis of
morphology.
– For embryos in treatment group 1, individual labs
will then apply and document morphokinetic
parameters and any other information available from
the time-lapse imaging, according to local policy,
and select the embryos for transfer.
– Embryo selection will be cross-checked by a second
embryologist on the day of transfer/freezing to en-
sure allocation selection is done in adherence with
the randomised allocation. This cross-check will be
documented in the study database.
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Embryo transfer Randomised patients for fresh embryo
transfer will have their embryos transferred into the
uterus on either day 3 or day 5 after the egg collection
(or day 6 if applicable). The participating centre can
decide the day of embryo transfer and the number of
embryos to be transferred according to their local
protocols. Randomised patients for frozen embryo
transfer will have their embryos frozen either on day 3
or day 5 after the egg collection. The participating
centre can decide the day of freezing according to their
local protocols. The selection of embryos for subsequent
transfer is done prior to freezing, as per the randomised
allocation. The frozen embryos selected for subsequent
transfer are to be clearly marked to ensure correct
identification.
Criteria for discontinuing or modifying allocated
interventions {11b}
Participants will be able to withdraw their consent to
take part in the trial at any time without giving a reason.
Given the short duration and low risk of the
intervention, it is not foreseen that participants would
need to be withdrawn or have their treatment modified
during their study participation. However, clinicians may
withdraw participants from the trial if they feel it is in
the participant’s best interest. Withdrawal from the trial
will not affect their ongoing care. If consent is
withdrawn, data already collected up to the point of
withdrawal will be retained (in line with the UK Data
Protection Act 2018) and permission will be sought to
complete follow-up outcomes data collection. If partici-
pants withdraw their consent while embryos are still in-
cubating (days 2–6), couples will be advised to allow
their embryos to remain in the allocated incubator to
minimise any disturbance to the embryos.
Strategies to improve adherence to interventions {11c}
Participant adherence is not applicable in this trial. The
only risk of non-adherence is linked to the use of identi-
cal devices for both group 1 (TLI) and group 2 (undis-
turbed culture), meaning time-lapse imaging would be
available for inspection in group 2. This will be mitigated
as follows:
– Prior to being involved in the trial, embryologists
will receive study-specific training and will sign off
training documentation confirming their agreement
to adherence to allocation and retaining blinding.
– Assessment of morphokinetic parameters during
incubation of group 1 (TLI) embryos is always
documented in lab notes and can generally be
tracked through ongoing annotations of time-lapse
imaging, and this provides an audit trail that is avail-
able for monitoring compliance.
– Before embryo transfer or freezing, a second
embryologist will cross-check and confirm the selec-
tion based on the allocated treatment—i.e. based on
TLI for group 1 participants, and based on static
image assessment only for group 2 participants.
– Any non-adherence will be elicited and documented
on study CRFs.
Relevant concomitant care permitted or prohibited
during the trial {11d}
The design of this trial will be pragmatic. It will allow
centres to use a TLI system of their choice. The trial tests
the basic premise that undisturbed culture and/or
addition of morphokinetic parameters to standard embryo
assessment improves outcomes in IVF/ICSI treatment. It
does not aim to test and validate individual TLI systems
and algorithms. It is accepted that clinical protocols for
IVF and laboratory conditions will vary with each centre.
All clinical and laboratory elements of IVF/ICSI treatment
apart from the randomised intervention will be carried
out according to local centre protocols, ensuring only that
there is no variation across the three study arms in
temperature, culture medium and use of gas. There is no
contraindication to any other standard treatment;
however, to ensure robust methodology, the trial will
exclude participants who are concomitantly participating
in other interventional trials, or have planned pre-
implantation genetic diagnostics or screening (PGS/PGD),
as this would interfere with the embryo selection process.
Provisions for post-trial care {30}
Following the trial intervention, all further care, which
includes embryo transfer, pregnancy test and review
appointments, will be according to the standard care
pathway.
The Queen Mary University of London is the sponsor
for the UK arm of this trial. The university will obtain
and hold insurance policies for legal liabilities arising
from the trial. The recruiting sites are NHS units and
have indemnity arrangements in place which will cover
their liabilities in relation to their participation in the
study.
The sponsor of international sites will cover their own
indemnity for this trial.
Outcomes {12}
Primary outcome
The primary outcome is live birth.
Secondary outcomes
Clinical efficacy outcomes:
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1. Pregnancy rate (positive pregnancy test
approximately 2 weeks after embryo transfer) per
participant randomised
2. Successful clinical pregnancy rate (at least one
intrauterine gestational sac seen at 6–8 weeks of
gestation; multiple pregnancy counts as one clinical
pregnancy) per participant randomised
3. Clinical pregnancy rate per embryo transferred
(total number of gestational sacs seen on ultrasound
scan/total number of embryos replaced into the
womb)
4. Use of elective single embryo transfer (e-SET) per
participant randomised
5. Embryo utilisation rate (% of total embryos either
transferred or frozen)
Clinical safety outcomes
1. Multiple pregnancy (two or more gestational sacs
seen on ultrasound scan at 6–8 weeks) per clinical
pregnancy
2. Pregnancy loss
(i) Between positive pregnancy test and 6–8-week
scan per positive pregnancy test
(ii) Between 6- and 8-week scan and 12 weeks (early
miscarriage) per clinical pregnancy
(iii)Between 12 and 24 weeks per clinical pregnancy
(iv) Stillbirth per clinical pregnancy
3. Incidence of major congenital abnormalities per
participant randomised
4. Birth weight
5. Gestational age
6. Ectopic pregnancy per participant randomised
Live birth was chosen as the primary outcome as this
remains the most relevant outcome for participants,
clinicians and all stakeholders. Our secondary clinical
efficacy and safety outcomes were chosen as these have
the biological plausibility to be relevant to the trial
intervention and also are identified as important core
fertility outcomes to be reported in fertility trials.
Participant timeline {13}
The trial intervention will be an alternative method for
incubation and assessment of embryos created during
IVF/ICSI. There will be no extra added intervention for
the embryos. There will be no extra visits/intervention
for the participants (Table 1).
Sample size {14}
Sample size
The sample size calculation was based upon the primary
outcome of live birth. With a 5% overall significance
level (2.5% for each of the two main treatment
comparisons: TLI vs. standard care, and undisturbed
culture vs. standard care), we would require 514
participant randomisations per treatment arm to detect
an absolute increase in the primary outcome from 26.5
to 35.25% with 80% power. Allowing for 2% loss to
follow-up or withdrawal of consent would require 525
participants per treatment arm (1575 in total).
The comparison between experimental treatment arms
(TLI vs. undisturbed culture) will be performed with no
impact on sample size because we will carry out this
statistical test conditional to the rejection of at least one
of the primary comparisons planned (TLI vs. standard
care, or undisturbed culture vs. standard care). This
hierarchical approach permits to maintain the overall
type I error rate of 5%.
This trial uses the re-randomisation design, which was
described by Kahan et al. [9]. Requirements for the re-
randomisation design are as follows:
1. Patients are only re-randomised when they have
completed the follow-up period from their previous
randomisation.
2. Randomisations for the same patient are performed
independently.
3. The treatment effect is constant across all
randomisation periods.
Requirement 1 is fully satisfied, as participants will
have completed their previous round of treatment before
re-joining the study. Participants have an equal chance
of being randomised to either of the three trial arms, re-
gardless of their previous randomisation result, therefore
satisfying requirement 2. Finally, there is no anticipated
treatment effect, either in terms of efficacy or safety,
from one episode to the next.
It has been demonstrated that introducing re-
randomisation in a trial will not affect the validity of the
statistical analysis and results [9].
Recruitment {15}
The trial poster will be displayed in fertility clinics and
on the fertility pages of local trust websites for the
purpose of advertising the trial. Trial information will
also be given out at information evenings. Where
suitable, Patient Identification Centres (PIC) will be
utilised to identify patients referred to participating
fertility clinics from secondary care fertility clinics.
Assignment of interventions: allocation
Sequence generation {16a}
Sequence generation for randomisation will be done
using a secure web-based randomisation system immedi-
ately prior to randomisation and subsequent allocation
of intervention.
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The randomisation will be stratified by a fertility clinic
and minimised by the following:
1) Participant’s age (< 35 years, 35–40 years, > 40 years)
2) Type of planned first embryo transfer (fresh,
frozen).
Minimisation for both factors will include a 90%
weighting to introduce 0.9 as a stochastic factor for
allocation probability.
Concealment mechanism {16b}
The allocation sequence will be implemented using a
secure web-based randomisation system. The system will
be tested prior to deployment using dummy sequences.
Access to the live randomisation system is given only
to embryologists, who are the only staff unblinded to the
intervention. Each embryologist at centres uses a
personal, unique login and password to access the
randomisation system. User access and allocation of the
correct level of access is managed by the central trial
team. Introduction of weighting of minimisation factors
(as described above) will introduce a stochastic element
that ensures allocation sequences remain unpredictable.
Implementation {16c}
A secure web-based randomisation system will generate
the allocation sequence. Randomisation will be per-
formed on the day of fertilisation check. Participants sat-
isfying all the eligibility criteria for the trial will be
randomised into one of the three treatment arms in a 1:
1:1 ratio.
1) Time-lapse imaging
2) Undisturbed culture
3) Standard treatment
Randomisation will be done by a trained and delegated
embryologist member of the study team using a secure
web-based randomisation system hosted by epiGenesys,
University of Sheffield, which is accessible around the
clock, 365 days of the year. Back-up procedures in case
of technical issues with accessing the randomisation
Table 1 Schedule of assessments
Baseline Day of
egg
collection
(D0)
Day of
fertilisation
check (D1)
Days 3, 5
and
optionally
day 6
Routine visit to fertility
unit approx. 2 weeks after
embryo transfer
Approx. 8
weeks of
gestation
Approx. 24
weeks of
gestation
Approx. 6 weeks
after the
expected due
date
Informed consent X
Confirmation of
informed consent
X
Baseline demographic
and clinical data
X
Randomisation and
confirmation to
randomised participants
X
Ineligible consented
participants informed
X
Embryo grading;
transfer if appropriate
X
Documentation of
morphokinetic
parameters (arm 1 only)
X
Pregnancy test
outcome
X
Elective single embryo
transfer rate
X
Clinical pregnancy rate X
Multiple pregnancy rate X
Miscarriage rate X
Live birth rate X
Stillbirth rate X
Multiple birth rate X
Serious adverse events X X X X X
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system will be made available and described in a study-
specific standard operating procedure (SOP).
Assignment of interventions: blinding
Who will be blinded {17a}
It will not be possible to blind embryologists to the
intervention. The trial statistician is ‘semi-blinded’ to the
allocation—they will see data by trial arms for DMC
report generation, but trial arms will not be identified. All
other local and central trial staff, including clinicians
performing the embryo transfer and data analysts, will be
blinded. Participants will be blinded to the allocated
intervention until the end of their participation in the
trial. This will either be a negative pregnancy test which is
approximately 2 weeks after embryo transfer or the end of
their pregnancy. Once randomisation is performed,
embryologists will document the allocation in a local
randomisation form that will remain in the lab to prevent
unblinding and proceed with the intervention and
laboratory procedures described below. A randomisation
log will be kept in the lab and accessed and updated by
study embryologists only.
Procedure for unblinding if needed {17b}
Local delegated embryologists will be the holders of the
code break list for each site. Given the low risk of the
intervention, it is unlikely that urgent unblinding should
be required to guide patient management. In the unlikely
event that an emergency codebreak is requested, the PI or
healthcare professional will request unblinding from the
embryologist. On receipt of the treatment allocation
details, the PI or treating healthcare professional will
continue to deal with the participant’s medical emergency
as appropriate. The PI must document the breaking of the
code and the reasons for doing so on the CRF/data
collection tool, in the site file and medical notes.
Additionally, participants may request to be informed of
their allocation when they reach the end of their study
participation (either due to unsuccessful pregnancy or end
of pregnancy). Care will be taken not to disclose the
allocation to any other member of the research team.
Any unblinding, including accidental unblinding
(which constitutes a protocol deviation), will be reported
to the Data Monitoring Committee (DMC) and included
in the final study report.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Trial data will be recorded by the research team at each
of the participating centres directly onto trial-specific se-
cure password-protected electronic case report forms
(eCRFs) in a database administered by epiGenesys, Uni-
versity of Sheffield. Data that is entered directly by the
embryologists (randomisation data and intervention
data) will be restricted to allow access only to unblinded
staff members.
The following data will be collected:
1) Baseline demographic data (age, ethnicity)
2) Baseline clinical data (category of infertility, type of
infertility, duration of infertility, BMI, treatment
attempt, parameters of egg reserve and sperm
count)
3) Clinical treatment data (stimulation protocol, drug
dosages, duration of stimulation, number of oocytes
retrieved, type of insemination procedure, number
of embryos available, fresh/frozen transfer, day of
embryo transfer, number of embryos transferred
and type of time-lapse machine, embryo grading; if
applicable, documentation of morphokinetic param-
eters will be documented and submitted separately
by embryologists to maintain blinding of the
remaining study team)
4) Data for all clinical outcomes (live birth, pregnancy
test outcome, implantation, clinical pregnancy,
multiple pregnancy, miscarriage, stillbirth, neonatal
data)
For all participants, clinical and laboratory data are
routinely recorded in the fertility medical notes or
fertility electronic database by clinical staff. If clinical
outcome data are not available in the medical records, a
trained delegated member of the research team will
phone the participants to obtain this data. Trained and
delegated members of the trial team, as documented on
the trial delegation log, will be responsible for the
completion of the eCRFs.
Plans to promote participant retention and complete
follow-up {18b}
If consent is withdrawn, data already collected up to the
point of withdrawal will be retained, and permission will
be sought to complete follow-up outcomes data collec-
tion. The duration of the intervention is short, and
follow-up procedures are part of standard care due to
HFEA reporting requirements; hence, we do not antici-
pate issues with follow-up.
Data management {19}
All data management will be undertaken by the Queen Mary
University of London. Standard operating procedures will be
in place for the collection and handling of data received at
the centre. All study data will be entered into a secure,
bespoke electronic trial database with restricted access. Data
collected on the data collection forms and entered onto the
electronic database will only identify the participants by a
unique trial number.
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Data will be processed on a workstation by authorised
staff. The workstations access the network via a login
name and password. No data are stored on individual
workstations. Backing up is done automatically overnight
to an off-site storage area. Sites will allow access to source
data and documentation for the purpose of monitoring,
auditing and inspections, for the relevant authorised
individuals.
Confidentiality {27}
The investigator has a responsibility to ensure that
patient anonymity is protected and maintained. They
must also ensure that their identities are protected from
any unauthorised parties. Information with regard to the
study patients from UK sites will be kept confidential
and managed in accordance with the Data Protection
Act (2018), NHS Caldecott Guardian, principles, The
Research Governance Framework for Health and Social
Care, and Research Ethics Committee Approval.
International sites will abide by their own countries
regulatory requirements.
The trial will collect personal data and sensitive
information about the participants either directly or
from their clinical team. Participants will be informed
about the transfer of this information to the study office
and will be asked to consent to this. The data will be
entered onto a secure computer database, either by trials
unit staff or directly via a secure internet connection.
Any data to be processed will be pseudo-anonymised. At
recruitment, eCRFs will be pseudonymised using a
unique participant code that is allocated by the recruit-
ing member of staff. At randomisation, an additional
unique code will be generated by the online randomisa-
tion system and recorded on the randomisation form.
All personal information obtained for the trial will be
held securely and treated as strictly confidential. All
staff, at each hospital and the trials unit, share the same
duty of care to prevent unauthorised disclosure of per-
sonal information. No data that could be used to identify
an individual will be published. The chief investigator,
Dr. Priya Bhide, is the ‘custodian’ of the data.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
Not applicable as no biological specimens will be
collected as a part of this trial.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Analyses will be intention-to-treat, will include all ran-
domised participants and will analyse according to the
treatment group to which they were randomised. We
will analyse each participant randomisation as an inde-
pendent observation (i.e. perform an independence ana-
lysis). As a sensitivity analysis, we will provide results
from analyses restricted to complete cases, for compari-
son with results based on multiple imputation.
For each analysis, we will present the treatment effect
(difference in means for a continuous outcome and an
odds ratio for binary outcomes) along with a 95%
confidence interval and a two-sided p value. Because we
have two main treatment comparisons (TLI vs. standard
care, and undisturbed culture vs. standard care), the sig-
nificance level for the primary outcome is set at 2.5% for
each treatment comparison. The primary outcome (live
birth) will be analysed using logistic regression model
and will be adjusted for stratification and minimisation
factors and other pre-specified covariates to increase
power. The stratification factor is the fertility clinic and
the minimisation factors are participant’s age (< 35 years,
35–40 years, > 40 years) and type of planned first embryo
transfer (fresh, frozen). Other covariates to be included
in the analyses are treatment attempt, type of infertility
(primary/secondary), category of infertility, duration of
infertility, BMI, type of time-lapse imaging equipment,
method of insemination (IVF vs. ICSI), number of re-
trieved oocytes and number of available embryos. A full
statistical analysis plan will be developed and finalised
prior to data analysis and will include full specifications
on subgroup analyses.
Interim analyses {21b}
No interim analyses or early stopping rules are foreseen.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
A full statistical analysis plan will be developed and
finalised prior to data analysis and will include full
specifications on subgroup analyses.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
Analyses will be intention-to-treat, will include all ran-
domised participants and will analyse according to the
treatment group to which they were randomised.
Missing data (for independent variables and outcome
data) will be imputed using multiple imputation via
chained equations.
Plans to give access to the full protocol, participant level-
data and statistical code {31c}
The trial summary is available in the public domain on
the ISRCTN registry.
Data sharing: Following primary publication of the
trial results, fully anonymised trial data and statistical
analysis code can be made available to interested
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researchers, where appropriate, on request to the Chief
Investigator.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
Trial management
The UK arm of the study is sponsored by the Queen
Mary University of London (QMUL) and conducted by
the Barts Research Centre for Women’s Health (BARC).
International sites will have their own separate sponsor.
QMUL will also have main oversight on a global level.
The trial will be coordinated and managed on a day-to-
day basis by the Trial Management Group (TMG) com-
prising of core members from the co-applicants and the
BARC. The Co-Investigators Group (CIG), Data Moni-
toring Committee (DMC) and Trial Steering Committee
(TSC) will provide strategic direction. Appointment of
the TSC and DMC will remain the responsibility of the
TMG.
Trial Management Group (TMG)
The TMG will comprise the chief investigator, co-
investigators, senior trials manager, trial coordinator,
embryology representative, clinical trial practitioner and
statistician. The TMG will be based at QMUL and meet
monthly. They will have overall responsibility for the
conduct of the trial and will report to the TSC.
Trial Steering Committee
The trial will be supervised by a single international
independent Trial Steering Committee (TSC). The TSC
will have an independent chair and at least two further
independent members, such as a clinician, embryologist
and a PPI representative. The TSC will meet biannually.
The CI, co-applicants, trials coordinator and senior trials
manager will be invited to attend the TSC meetings. The
specific tasks of the TSC will be:
 To recommend and approve major amendments to
the protocol arising during the trial
 To receive the reports from the TMG and DMC
 To approve the statistical analysis plan and any
changes thereto
 To resolve problems brought to it by the trial
collaborators
 To review trial reports and the main paper for
publication
Co-Investigators Group
The Co-Investigators Group (CIG) will comprise the
chief investigator, co-investigators, key staff from QMUL
and principal investigators and key staff from the
recruiting centres. They will provide strategic direction
to the trial and will meet twice during the course of the
trial, during recruitment and in the data analysis phase.
The clinical trial report will be submitted to the CIG
and TSC for review before publication.
The timing, content and remit of the committee
meetings will be decided at the first meeting.
Composition of the data monitoring committee, its role
and reporting structure {21a}
A single international independent Data Monitoring
Committee (DMC) will be established for the trial. It
will comprise of an independent chair and at least two
further independent members who are experts in the
field, such as a clinician, trial methodologist and
statistician. The DMC will meet biannually.
Collaborators and all others associated with the trial
may write through the trial office to the DMC, to draw
attention to any concern they may have about the
possibility of harm arising from the treatment under
study, or about any other matters that may be relevant.
The DMC has the right to review unblinded data
reports. The DMC will also monitor the progress of the
trial and will report to the TSC.
Adverse event reporting and harms {22}
Adverse events (AE)
An AE is any untoward medical occurrence in a trial
participant, including occurrences which are not
necessarily caused by or related to the trial intervention.
An AE can therefore be any unfavourable and
unintended sign (including an abnormal laboratory
finding), symptom or disease temporarily associated with
trial activities.
Due to the high incidence of adverse events
routinely expected in this patient population and the
low risk of the intervention, only those adverse events
identified as serious will be recorded for the trial.
Serious adverse event (SAE)
A serious adverse event (SAE) is defined as an untoward
occurrence that:
(a) Results in death
(b) Is life-threatening
(c) Requires hospitalisation or prolongation of existing
hospitalisation, apart from the following events
which are foreseeable in pregnant women
undergoing IVF/ICSI and hence will not require
reporting as SAEs:
Events relating to the participant:
1. Mild/moderate ovarian hyperstimulation
syndrome (not requiring paracentesis)
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2. Pelvic infection/pelvic inflammatory disease
3. Multiple pregnancy
4. Miscarriage
5. Ectopic pregnancy
6. Any other hospitalisations for known pregnancy
complications
7. Any other hospitalisations for known
postpartum complications
8. Any hospitalisations for labour
Events relating to the baby:
1. Low/very low birth weight
2. Small/large for gestational age
3. Preterm/very preterm delivery
(d) Results in persistent or significant disability or
incapacity
(e) Consists of a congenital anomaly or birth defect
(f) Is otherwise considered medically significant by the
investigator.
N.B. Any event requiring admission to the neonatal
intensive care unit (NICU) other than those listed above
is to be reported as SAEs.
All congenital anomalies are to be reported as SAEs,
whether identified at birth or earlier (e.g. cause for
miscarriage or termination).
Events that fulfil the criteria for seriousness and are not
amongst the above list will need to be reported as SAEs.
They also need to be assessed as to whether they are
(possibly, probably or definitely) related to administration
of trial procedures.
Any SAEs that are (possibly, probably or definitely)
related to the trial procedures will also need to be
assessed as to their expectedness. As there are no
expected adverse effects of TLI, any events that are
considered by the local investigator to be related to the
use of a TLI device will be classed as unexpected.
Notification and reporting of serious adverse events
Data on SAEs will be documented from randomisation,
at the scheduled outcome assessment points from the
medical records, and up to 6 weeks post-delivery in case
of successful pregnancies. This may include telephone
contact with the mother approximately 6 weeks after de-
livery if required. Research staff should refer to all avail-
able resources including medical records, online systems
such as CRS, and discussions with participants them-
selves to ensure that all reportable SAEs are elicited.
Any SAEs that require reporting need to be reported
by the local PI to the chief investigator (CI) within 24 h
of learning of the event. The CI will assess the event and
can always upgrade the relationship or severity of the
event, but never downgrade it. The CI will assess if a
‘related’ SAE was ‘unexpected’. Serious adverse events
(SAEs) that are considered to be ‘related’ and
‘unexpected’ are then to be reported to the sponsor
within 24 h of learning of the event and to the Research
Ethics Committee (REC) within 15 days in line with the
required timeframe. International sites will report to the
QMUL sponsor in addition to their own sponsor.
Other safety considerations and reporting
The CI may need to take urgent safety measures to
ensure the safety and protection of the clinical trial
subjects from any immediate hazard to their health and
safety. The measures will be taken immediately. In this
instance, the approval of the REC prior to implementing
these safety measures is not required.
The CI will send the annual progress report to the
main REC on the anniversary date which is the date of
the REC favourable opinion, as well as to the sponsor.
The DMC will review reports of ‘related’ and
‘unexpected’ SAE. If appropriate, it will make
recommendations for the continuance of the trial or
modification of the study protocol.
Frequency and plans for auditing trial conduct {23}
The sponsor has assessed the study as low risk for the
purpose of quality control. The study sites will therefore
perform trial self-monitoring according to the agreed
trial monitoring plan and self-monitoring template. Trial
monitoring will include source data verification checks
on informed consent forms and eligibility for randomisa-
tion and a sample set of CRFs. The self-monitoring re-
ports will be reviewed by QMUL and all findings will be
followed up and actioned as per the trial monitoring
plan. The study sites will return self-monitoring tem-
plates to QMUL every 6 months.
In addition, central data monitoring will be performed
by the central trial team, by identifying outliers and
missing data through regular data monitoring reports.
Central data administration staff will issue data queries
to sites.
The sponsor has the right to carry out an internal
audit throughout the duration of the trial.
A study may be identified for audit by any method
listed below:
1. A project may be identified via the risk assessment
process.
2. An individual investigator or department may
request an audit.
3. A project may be identified via an allegation of
research misconduct or fraud or a suspected breach
of regulations.
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4. Projects may be selected at random. The
Department of Health states that Trusts should be
auditing a minimum of 10% of all research projects.
5. Projects may be randomly selected for audit by an
external organisation.
Audits of UK sites will be conducted by a sponsor’s
representative.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
The trial can only start after approval from a REC, the UK
Health Research Authority (HRA) and confirmation of
local capacity and capability at each of the participating
centres (or equivalent ethics committee bodies for
international sites). If there is any further safety
information which may result in significant changes in the
risk/benefit analysis, the protocol, PIS and ICF will be
amended accordingly and submitted to the REC for
revision and approval. All participants that are actively
enrolled on the study will be informed of the updated
information and given a revised copy of the PIS/ICF in
order to confirm their wish to continue on the study (if
feasible), if it may change their willingness to participate.
Dissemination plans {31a}
1. The CI will have primary responsibility and
coordinate dissemination of data from this trial. A
core team consisting of the co-investigators will
work closely with QMUL to plan and effectively
disseminate the findings of the research to all stake-
holders: participants, clinical community, user
groups, funding bodies, NHS commissioners and
the general public. The clinical trial report and the
main manuscript will be reviewed by the CIG and
TSC before publication.
2. Dissemination to clinicians and clinical professional
bodies will be through publications and
presentations at major national and international
conferences relevant to the speciality. We aim to
publish the findings in the highest impact peer-
reviewed journals and present them at the annual
conferences related to the speciality. We plan to
publish the study protocol in an open-access journal
and to communicate the trial findings to the
Cochrane Gynaecology and Fertility Group with a
view to incorporate the results into the current
Cochrane review.
3. Dissemination to the participants and the general
public will be done through newsletters, NHS
websites and through the meetings and websites of
local PPI networks and Fertility Networks UK. In
consultation with the investigators and appropriate
journals, a press release will be issued to the media
upon publication of the results.
4. A writing committee will be appointed which will
follow the authorship criteria used by high-impact
peer-reviewed journals (www.icjme.org). Members
of the committee will be named authors on the trial
monograph and principal study paper. Other team
members with substantial contribution to the trial
will be formally acknowledged in publications aris-
ing from the trial.
5. There is currently no national guidance on the use
of time-lapse imaging in IVF/ICSI. The NICE guide-
line development process will be informed of the re-
sults of the trial, which will be important for their
guideline updates.
6. Time-lapse imaging is currently not incorporated
into national IVF/ICSI tariffs. The costing of IVF
may need to be revised in order to include the costs
of time-lapse imaging into routine NHS funded
IVF/ICSI care. We plan a dissemination event in-
volving the NHS commissioners and funding stake-
holders with a view to incorporating the findings of
the study into NHS funding, practice and policy.
7. Data sharing: following the primary publication of
the trial results, fully anonymised trial data can be
made available to interested researchers on request
to the chief investigator and approval from the
sponsor.
Discussion
Time-lapse imaging of embryos during IVF/ICSI
treatment is a newer technology hypothesised to improve
outcomes of treatment. This may be due to the provision
of undisturbed culture conditions for the embryos and/or
improving the predictive accuracy of embryo selection.
The presence of two variables necessitates a three-arm
trial. However, the current best evidence for the use of
time-lapse imaging in IVF/ICSI is inconclusive. Previous
RCTs have typically used the clinical pregnancy rate as a
surrogate outcome for the live birth rate, which remains
the most relevant outcome for patients, clinicians, and
policymakers. Furthermore, the long-term safety of this
procedure is unknown. The above-mentioned Cochrane
reviews as well as the consensus from our preparatory sur-
veys amongst clinicians, embryologists and patients have
shown that a definitive conclusive trial is necessary.
TLI in IVF/ICSI is commercially available, extensively
marketed and widely introduced in IVF clinics in spite
of inconclusive evidence regarding its effectiveness and
its considerable additional expense to clinics. It is a
worrying trend to see a newer but expensive technology
being introduced very rapidly into practice without high
levels evidence of its clinical and cost-effectiveness or
Bhide et al. Trials          (2020) 21:600 Page 15 of 17
safety. In the absence of high-quality evidence and slip-
ping clinical equipoise, it is necessary to urgently per-
form a large randomised controlled trial to confirm or
refute the benefit of time-lapse imaging in IVF/ICSI.
This trial will also generate a dataset which will
remain a useful resource for future health economic
assessment and assessment of maternal and perinatal
outcomes. Furthermore, the trial will create a cohort of
children exposed to the intervention from which long-
term safety data may be collated through follow-up stud-
ies conducted in the future.
Trial status
The current version of the study protocol is v7.0, 04
September 2019. Recruitment began on 27 June 2018
and the recruitment target is expected to be reached by
28 February 2021.
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